Background: Omalizumab, a recombinant monoclonal anti-IgE antibody, was devel-
| INTRODUCTION
Severe asthma affects 5%-10% of asthmatic patients who require treatment with high-dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming "uncontrolled" or which remains "uncontrolled" despite this therapy. 1 Omalizumab is a humanized recombinant monoclonal anti-IgE antibody developed for the treatment of allergic diseases and severe allergic asthma. The anti-IgE antibody reduces serum IgE levels and IgE receptor expression on inflammatory cells to interrupt the allergic cascade. 2, 3 Omalizumab has been demonstrated to be an effective treatment of atopic asthma, improving asthma controls, 4 decreasing acute exacerbation, hospitalization, 5 steroids requirement in allergic asthmatics 6, 7 and improving quality of life of patients with severe persistent allergic asthma that is inadequately controlled by currently available asthma medications. Patients who benefit most from omalizumab therapy are those receiving high doses of ICS, those with a history of frequent emergency asthma treatment, and those with poor lung function. 8 However, the mechanisms behind how anti-IgE treatment influences the pathophysiologic responses remain to be elucidated. Furthermore, only around 64% response rate is seen after 16 weeks of anti-IgE treatment in terms of various aspects of response. 8 In order to identify potential biomarkers for response to anti-IgE therapy, we studied the mechanisms of action of omalizumab in severe allergic asthma patients through the comparison of proinflammatory cytokine profiles in the bronchial tissues.
| MATERIALS AND METHODS

| Study subjects
We prospectively recruited 23 patients with severe allergic asthma (56.4 ± 2.1 years old, 11 females) with increased serum IgE levels (599.0 ± 111.8 IU/mL) and persistent asthma symptoms (Asthma Control Test [ACT] scores <19, 13.65 ± 0.49), impaired pulmonary function (FVC 35.6 ± 5.6% predicted and FEV 1 38.7 ± 3.0% predicted), unable to achieve a level of mild-to-moderate persistent asthma under either continuous or near-continuous oral corticosteroids, high-dose ICS, or both. All the patients in this study were regularly followed up at our clinic for more than 3 years. The adherence to asthma treatment was repeatedly checked their monthly prescription refill records to ensure their lose of asthma control was not attributed to poor adherence to medications.
Patients with difficult asthma control were excluded from this study if appropriate diagnosis or treatment of the confounders vastly improves their conditions. All asthmatic patients met reimbursement criteria and were treated with anti-IgE antibody therapy (omalizumab) monthly for 4 months. The dosage of omalizumab for study subjects was determined according to their serum IgE levels. 8 All the antiasthma medications were continuously used without any change during omalizumab treatment. Five asthmatic patients with minimal symptoms and nearly normal pulmonary function (Mild Asthma) using inhaled beclomethasone (0-1000 μg/d or equivalent)
were recruited as control subjects for the severe allergic asthma patients (Table 1 ). All asthmatic patients underwent fiberoptic bronchoscopy before omalizumab treatment in order to obtain bronchial biopsy specimens. 9 Nine patients who were responsive to omalizumab treatment gave their consents to a follow-up bronchoscopy after 4 months of omalizumab treatment. All asthmatic patients had no respiratory infection within 3 months prior to bronchoscopy, and received spirometry and ACT scores measurement before and after omalizumab treatment. Those patients who achieved an increase in ACT score more than 3 after omalizumab treatment were categorized as omalizumab responders (Responder); 10 those who failed to improve their asthma control (increase in ACT scores <3) were categorized as omalizumab nonresponders (Non-Responder). Fraction of exhaled nitric oxide (FeNO) measurement is beneficial to identify type 2 airway inflammation, and clinical response to ICS. In some studies, FeNO-guided management may also improve adherence to anti-inflammatory therapy, and the ability to predict exacerbations or decline in lung function. 11 However, FeNO is not reimbursed in Taiwan and was not used as a routine examination for asthma control assessment. In this study, not all the study subjects were willing to self-pay for FeNO measurement. 
| Analysis of bronchial biopsies
Fiberoptic bronchoscopy was performed in all asthma subjects under sedation with midazolam and bronchial biopsies were obtained. The inflammatory state was assessed by counting eosinophils and neutrophils (stained with anti-EG2 and antineutrophil elastase antibodies, respectively). 12 The presence of eosinophilic inflammation was defined by eosinophil counts > 10 per mm 2 while mixed eosinophilic and neutrophilic phenotype was defined by neutrophil counts >2
per mm 2 and eosinophil counts >10 per mm 2 .
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| Statistical analysis
We used Mann-Whitney test and Kruskal-Wallis analysis to determine the statistical significance of differences between groups, and , upregulated mRNA expression of type 2 cytokines in bronchial tissues. *P < 0.05, **P < 0.01 compared with Non-Responder; # P < 0.01 compared with mild asthma. Data are presented as mean ± SE (standard error).
Wilcoxon matched-pairs test was used to determine within-group differences. Fisher's exact tests were used to determine the significant differences between groups in terms of gender and smoking status. P < 0.05 was considered statistically significant. Data were analysed by using Prism 7 (GraphPad Software Inc, La Jolla, CA, USA).
| RESULTS
| Clinical characteristics
Among 23 patients with severe allergic asthma, 14 improved their asthma control by increasing ACT scores more than 3 after 4 months of omalizumab treatment (Responders), while nine failed to improve asthma control (ACT scores increased <3, Non-Responders). Patients in Responders were more female predominant, nonsmokers, eosinophilic airway inflammation and had higher FeNO levels, worse asthma control and FVC, compared with Non-Responders ( Table 1) .
| Cytokine expression in bronchial tissues
Quantitative PCR analysis of type 2 cytokines in the bronchial tissues of all the study subjects. Among type 2 cytokines, only IL-13 and IL-9 mRNA expression was found significantly higher in (Figure 1) . Most of Responders were type 2-high endotype (12/14), while only one patient in Non-Responders was type 2-high endotype (1/9, Table 1 
| Clinical response to anti-IgE therapy
For those in Responder group, the improvement in ACT scores was accompanied by an improvement in their pulmonary function after 4 months of omalizumab treatment ( Figure 3A) . Interestingly, those in Non-Responder group also had a significant improvement in FEV 1 , though to less extent than Responders, after omalizumab treatment ( Figure 3A ). There was no significant difference in (Table 2) . However, subjects of Partial control group had more rhinosinusitis comorbidities and most patients (7/8) had a mixed eosinophilic and neutrophilic airway inflammation than those of well-control group (Table 2) .
| DISCUSSION
In the present study, we have demonstrated that patients with severe allergic asthma who were responsive to anti-IgE therapy (omalizumab) had higher mRNA expression of type 2 cytokines, IL-13 and IL-9, and epithelium-derived cytokines IL-33, IL-25 and TSLP in their bronchial tissues. Treatment of omalizumab for 4 months significantly decreased those upregulated cytokine mRNA, accompanied by a significant improvement in asthma control status, pulmonary function and exacerbation frequency.
Most of omalizumab responders were of type 2-high endotype. Type 2 cytokines also can be released by activated type 2 innate lymphoid cells (ILC2), including IL-9, 16 which are steroid resistant. 17 Our results are compatible with previous reports to confirm the role of anti-IgE in allergic asthma treatment because type 2 cytokines mediated inflammation was attenuated after anti-IgE treatments. 5, 8, 18 The mechanisms responsible for dysregulated Th2-mediated immune response are various, 19 effects. 35, 36 The need of macrolides in our patients of partial F I G U R E 6 There was no significant difference in IL-33, IL-25, TSLP, IL-13 or IL-9 mRNA expression in the bronchial tissues among severe allergic asthma patients who partially responded to 12-mo omalizumab treatment (partial control, n = 8) and those who achieved well control of their asthma (well control, n = 6). *P < 0.05, **P < 0.01 ***P < 0.001 
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